← Back to Clinical Trials
Recruiting NCT05099432

NCT05099432 The CARMA Technique Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05099432
Status Recruiting
Phase
Sponsor Princess Alexandra Hospital, Brisbane, Australia
Condition Colonic Polyp
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2021-11
Primary Completion 2023-05

Eligibility & Interventions

Sex All sexes
Min Age 16 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
CARMA technique

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2021-11 with a primary completion date of 2023-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Colonoscopic removal of polyps is an important and well-established tool in the prevention of colorectal cancers. However, high polyp recurrence rates after endoscopic resection, with resultant development of interval cancers, remains a problem; this most commonly stems from unrecognised incomplete polyp resection. Thus, a standardised endoscopic technique is needed that will allow endoscopists to consistently achieve a clear margin of resection. The investigators believe the Cap Assisted Resection Margin Assessment (CARMA) technique will address this problem. This novel technique focuses on a standardised assessment of the resection margin after endoscopic polypectomy utilising available standard high-definition video endoscopes with imaging features including narrow band imaging (NBI) and magnification endoscopy.

Eligibility Criteria

Patients with colonic polyps will be considered following below criteria Inclusion Criteria: \- any polypectomy (though only a maximum of two polyps from one individual participant) Exclusion Criteria: * polyps less than 10mm which were resected under endoscopic view with a definite \> 1mm clear margin * scar site recurrence polyps * polyps with endoscopic evidence of invasion * pedunculated polyps * pseudopolyps * participants who will not be available for follow up endoscopy

Contact & Investigator

Central Contact

Alexander Huelsen, MD

✉ alexander.huelsenkatz@health.qld.gov.au

📞 +61 7 3176 2111

Principal Investigator

Alexander Huelsen, MD

PRINCIPAL INVESTIGATOR

Princess Alexandra Hospital

Frequently Asked Questions

Who can join the NCT05099432 clinical trial?

This trial is open to participants of all sexes, aged 16 Years or older, studying Colonic Polyp. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05099432 currently recruiting?

Yes, NCT05099432 is actively recruiting participants. Contact the research team at alexander.huelsenkatz@health.qld.gov.au for enrollment information.

Where is the NCT05099432 trial being conducted?

This trial is being conducted at Woolloongabba, Australia.

Who is sponsoring the NCT05099432 clinical trial?

NCT05099432 is sponsored by Princess Alexandra Hospital, Brisbane, Australia. The principal investigator is Alexander Huelsen, MD at Princess Alexandra Hospital. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology